You are browsing articles on the topic of Vascular Archives - CardioExchange

Avatar of Larry Husten, PHD

Economic Study Finds VTE Prophylaxis with Low-Molecular-Weight Heparin Cost Effective (3 Nov 2014)

News

Critically ill patients in the hospital are at high risk for developing venous thromboembolism (VTE). The 2011 PROTECT trial compared the two most common drug strategies used to prevent VTE — unfractionated heparin (UFH) and dalteparin, a low-molecular-weight heparin (LMWH) —  and found no difference between the two groups in the primary endpoint of the trial, leg deep-vein thrombosis….

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

First Drug-Coated Balloon Approved by FDA for Leg Blockages (13 Oct 2014)

News

The FDA today announced that it had approved for use in the U.S. the first drug-coated angioplasty balloon catheter to re-open blocked arteries in the superficial femoral and popliteal arteries. The Lutonix 035 Drug Coated Balloon Percutaneous Transluminal Angioplasty Catheter (Lutonix DCB) is manufactured by CR Bard and has been available in Europe since 2012. “Peripheral artery disease can be quite serious….

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Lower Rate of Microvascular Complications in Statin Users Who Develop Diabetes (9 Sep 2014)

News

In recent years, the medical community has become increasingly aware that taking statins can result in slightly higher glucose levels, and this can lead to a diagnosis of diabetes in a small but statistically significant number of people. But it has been unclear whether the diagnosis of diabetes in people taking statins also places them…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Kristin

FDA: Risk for Venous Thromboembolism with All Testosterone Products (23 Jun 2014)

News

The FDA is requiring an expanded label change to all approved testosterone products to warn of the increased risk for venous thromboembolism. Labels currently address the risk for clots associated with polycythemia caused by testosterone treatment. The action follows reports of blood clots in testosterone users unrelated to polycythemia. The agency says the warning is…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Joe

Vena Cava Filters Reduce Pulmonary Emboli But Increase VTE Recurrence Tenfold (6 Mar 2014)

News

Inferior vena cava filters seem to offer protection against death from pulmonary embolism when compared with anticoagulant therapy, but they have no significant effect on all-cause mortality. In addition, the filters are associated with higher rates of recurrent venous thromboembolism, according to an article in the Journal of the American College of Cardiology. Researchers examined…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Stent Remains Available Despite Trial Showing Dangers (24 Jan 2014)

News

A leading critic says that the FDA has been remiss for not removing a stent from the market although strong evidence exists that its use leads to more deaths and strokes. The Wingspan intracranial stent, manufactured by Stryker Neurovascular, was approved in 2005 by the FDA through the humanitarian device exemption (HDE) for the rare…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Joyce

Nontechnical Skills Matter in the Cardiac Operating Room (9 Sep 2013)

Voices

Joyce Ann Wahr, M.D. and Harlan M. Krumholz, MD, SM

Joyce A. Wahr discusses the importance of teamwork and communication in performing cardiac surgery, as described in a new AHA scientific statement.

Avatar of Larry Husten, PHD

American Heart Association Announces Late-Breaking Clinical Trials (28 Aug 2013)

News

There are still a few days left in August, and the European Society of Cardiology meeting doesn’t start until this weekend in Amsterdam. Nevertheless, the American Heart Association has released the list of late-breaking clinical trials for its annual meeting in November. Late-Breaking Clinical Trials 1: Acute Cardiovascular and Cerebrovascular Care Sunday, Nov 17, 2013, 4:00 PM –…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Sachin

How Do Patients with CAD Fare After TAVR? (3 Jun 2013)

Voices

Sachin Goel, MD and Erica Sarah Spatz, MD, MHS

Sachin Goel discusses his research group’s literature review focusing on patients with coronary artery disease who are evaluated for — and those who undergo — transcatheter aortic valve replacement.

Avatar of Behnood Bikdeli, M.D.

Should the Use of IVC Filters be Filtered Until We Have More Data? (26 Mar 2013)

Voices

Behnood Bikdeli, M.D.

There’s been a remarkable increase in the use of IVC filters, but what is the evidence base behind this mechanistically appealing approach?